SCHEMBL4468650

SCHEMBL4468650

COc1ccc(C2CC(=O)N(C(C)C(=O)O)C2)cc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 9/20 0.57
PDE4B Q07343 8/20 0.57
PDE4C Q08493 7/20 0.57
PDE4D Q08499 7/20 0.57
CSF1R P07333 2/20 0.49
APP P05067 2/20 0.46
SMPD1 P17405 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
THRB P10828 1/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462117 0.88 PDE4A (0.53) PDE4APDE4BPDE4CPDE4D
SCHEMBL4465498 0.83 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL13677930 0.82 PDE4A (0.71) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL3905579 0.80 PDE4B (0.59) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL5194407 0.79 PDE4A (0.53) PDE4APDE4BPDE4CPDE4D
SCHEMBL13677657 0.78 PDE4A (0.62) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL3893978 0.78 PDE4A (0.62) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL13677667 0.77 PDE4A (0.67) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL13677706 0.77 PDE4A (0.67) PDE4APDE4BPDE4CPDE4DCSF1R
SCHEMBL3896352 0.77 PDE4A (0.66) PDE4APDE4BPDE4CPDE4DCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306156-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2009-12-10 US disclosed
US-7585882-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2009-09-08 US disclosed
US-20060135535-A1 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis MEMORY PHARMACEUTICALS CORPORATION 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135535-A1 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis PDE4A, PDE4B, PDE12 PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885
US-20090306156-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE5A PDE4A 1/4885PDE4B 5/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.